<DOC>
	<DOCNO>NCT01451918</DOCNO>
	<brief_summary>Resveratrol , ingredient red wine available Canada highly purify form over-the-counter health supplement , show number health benefit . Data vitro animal study suggest beneficial effect insulin sensitivity lipid lowering . The investigator aware , however , mechanistic study examine effect highly purify resveratrol vivo lipoprotein metabolism human . Given potential therapeutic benefit resveratrol correct metabolic abnormality insulin resistant individual investigator plan examine effect resveratrol intestinal hepatic lipoprotein production human .</brief_summary>
	<brief_title>Regulation Intestinal Hepatic Lipoprotein Secretion Resveratrol</brief_title>
	<detailed_description>Subjects receive resveratrol ( Transmax 1 x 500mg tablet bid one week follow 2 x 500mg bid second week ( Biotivia Longevity Biologicals , New York , NY , USA ) placebo advise start take tablet 14 day prior first lipoprotein kinetics study . For lipoprotein kinetics study subject receive infusion stable isotope enrich leucine bolus stable isotope enrich glycerol order measure rate fatty acid synthesis , apolipoprotein triglyceride turnover respectively . This vivo stable isotope enrichment methodology widely establish used investigator around world 30 year examine metabolism various metabolite human . On first day 2 day admission hospital lipoprotein kinetics study , follow overnight fast , approximately noon day 1 study subject admit hospital 30ml fasting blood sample drawn analysis plasma glucose , total plasma cholesterol , LDL-cholesterol , HDL cholesterol , triglyceride ( TG ) , free fatty acid ( FFA ) , insulin , cytokine , stable isotope enrichment detailed analysis triglyceride rich lipoprotein ( TRL ) composition ( lipid apolipoprotein content ) . The subject allow eat regular meal day fast overnight 7pm . At 4am subject begin ingest first 17 identical small hourly aliquot liquid formula call Great Shake Plus ( Hormel ) , hourly dose equivalent 1/17th estimate daily caloric requirement calculate Harris-Benedict formula . Apart shake subject eat end study 7pm night . This provide steady state feed state subsequent assessment lipoprotein turnover kinetics . At 7am 2 iv 's inserted superficial vein forearm , one infusion one sampling . At 7 ( investigator refer time point 0hr lipoprotein turnover study ) , lipoprotein turnover study begin . An iv bolus deuterated-glycerol ( d5-glycerol , 75 micromol/kg ) administer , follow primed-constant infusion deuterated leucine ( L- [ 5,5,5-2H3 ] -leucine ; d3-leucine , 98 % , Cambridge Isotope Laboratories , Andover , MA , USA ) ( 10 micromol/kg bolus follow 10 micromol/kg/hr 10 hour ) . Blood sample collect prior regular time interval 10 hour iv bolus d3-glycerol ( 13C-triglyceride palmitate enrichment ass de novo lipogenesis ) start constant infusion d3-leucine ( assessment lipoprotein kinetics ) . Insulin sensitivity assess calculation HOMA-IR .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>1 . Men woman , age 23 60 year 2 . Fasting plasma triglyceride 2.0 5.0 mmol/l 3 . Body mass index 25 kg/m2 35 kg/m2 4 . Minimum body weight 64kg 5 . Hemoglobin 130g/L . 6 . Research volunteer must able provide inform consent willing comply protocol requirement . 7 . HOMAIR ( measure insulin resistance calculate fast blood glucose insulin ) &gt; 4.0 . 1 . Subject history hepatitis/hepatic disease active within previous two year . 2 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) , genitourinary , hematological system , severe uncontrolled treated untreated hypertension ( sit diastolic BP &gt; 90 systolic &gt; 140 ) proliferative retinopathy 3 . Any dehydration excessive vomit 4 . History diabetes 75g OGTT indicative diabetes . 5 . Cancer history cancer 6 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 7 . Any active medical illness 8 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 5mU/l &lt; 0.01 mU/l 9 . Any clinically relevant abnormal blood/urine screen test result outside normal reference range significant investigator exclude 10 . Any current hormonal disorder history hormonal disorder 11 . Any bleed disorder autoimmune condition 12 . Any allergy ingredient study product placebo ie : hypersensitivity resveratrol , grape , red wine , red wine polyphenols microcrystalline microcellulose 13 . Current addiction alcohol substance abuse determine investigator . 14 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 15 . Taking prescription nonprescription medication time study 16 . Taking natural health product course study 17 . Having donate blood three month prior three month post study procedures 18 . A pregnancy test perform 1 3 day prior study female subject ( visit # 4 , visit # 7 take study drug ) . Those test positive pregnancy exclude . 19 . If breastfeed lactate exclude study . 20 . Women take oral contraceptive pill exclude study . 21 . All current smoker smoke 1 pack per day 5 year . 22 . Those ferritin level 50 ug/L exclude 23 . Study Participants experience serious adverse event longer satisfy inclusion /exclusion criterion trial withdrawn</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Dyslipidaemia</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>